文献速递其他结缔组织病

托法替布治疗难治性幼年皮肌炎的初步研究

Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该初步研究纳入3例难治性幼年皮肌炎(JDM)患者,给予托法替布5 mg每日两次至少6个月,并评估PRINTO核心指标。3例患者均耐受良好并应答,肌力、皮肤病变、医生整体疾病活动度及炎症指标改善,未发生严重不良事件。作者认为托法替布可谨慎用于难治性JDM,仍需随机对照试验验证。

要点

  • 3例难治性JDM患者使用托法替布5 mg每日两次至少6个月,均耐受良好并应答。
  • 治疗后儿童肌炎评估量表、MMT-8、医生整体疾病活动度及炎症指标显著改善,未发生严重不良事件。
  • 托法替布可谨慎考虑用于难治性JDM,疗效仍需随机对照试验评估。

核心结论

  • 托法替布在部分难治性JDM病例中可改善肌力、皮损和日常生活质量,并有助于激素减量,但需谨慎使用且有待随机对照试验验证。

研究设计与样本

  • 初步研究(pilot study)联合文献综述;难治性JDM定义为两种及以上激素节约药物或大剂量激素治疗失败。
  • 3例难治性JDM患者接受托法替布5 mg每日两次至少6个月,采用PRINTO核心指标集在0、3、6个月评估。

主要发现

  • 3例受试者均耐受良好并对托法替布应答,儿童肌炎评估量表、MMT-8、医生整体疾病活动度及炎症指标显著改善。
  • 未发生严重不良事件;肌力改善、皮损消退、日常生活质量提高,激素成功减量。

关键数值与推荐

  • 难治性JDM定义:两种及以上激素节约药物或大剂量激素治疗失败。
  • 托法替布剂量:5 mg每日两次,疗程至少6个月;评估时点为第0、3、6个月。

临床怎么用

  • 对部分难治性JDM患儿可谨慎考虑使用托法替布,并在治疗中按PRINTO核心指标随访肌力、皮肤和炎症指标。

局限性

  • 本研究为初步研究,仅纳入3例患者,证据有限,疗效仍需随机对照试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: JDM is a rare autoimmune inflammatory muscle disease with a pronounced IFN signature. Treatment for children with JDM has improved over the years with the use of steroids and immunosuppressive agents. However, there remains a subset of children who have refractory disease. Janus kinase and type I IFN signalling production are suspected to contribute to the pathogenesis of JDM. Our pilot study investigated the use of tofacitinib, a Janus kinase inhibitor, in refractory JDM cases to provide new therapeutic options for better treatment. METHODS: Refractory JDM was defined as patients who failed two or more steroid sparing agents or high-dose steroids. Tofacitinib was given to three refractory JDM patients with a dose of 5 mg twice per day for at least 6 months. Core set measures defined by Pediatric Rheumatology International Trials Organization were evaluated at month 0, 3 and 6 along with other systemic evaluations. A literature review was conducted to identify all the cases using Janus kinase inhibitors in JDM. RESULTS: All three subjects tolerated and responded well to tofacitinib with significant improvement in Child Myositis Assessment Scale, manual muscle testing-8, physician global disease activity and inflammatory indices without occurrence of severe adverse events. CONCLUSION: This pilot study showed improvement of muscle strength, resolution of cutaneous lesions, increased daily quality of life and successful tapering of steroids when tofacitinib used in selected cases. Tofacitinib can be considered with caution when treating refractory JDM cases. Further randomized controlled trials are warranted to assess its efficacy in JDM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford). 2021. PMID: 33024992. doi:10.1093/rheumatology/keaa558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。